Transient Protection of Hematopoietic Stem and Progenitor Cells Against Ionizing Radiation
US-2016045509-A1 · Feb 18, 2016 · US
Tricyclic lactams for use in HSPC-sparing treatments for Rb-positive abnormal cellular proliferation
US10376519B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10376519-B2 |
| Application number | US-201715665071-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 31, 2017 |
| Priority date | Apr 17, 2014 |
| Publication date | Aug 13, 2019 |
| Grant date | Aug 13, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select Rb-positive cancers is disclosed using specific compounds disclosed herein. In certain embodiments, the compounds described herein act as selective cyclin-dependent kinase 4/6 (CDK 4/6) inhibitors when administered to subjects.
First claim
Opening claim text (preview).
We claim: 1. A method for treating retinoblastoma (Rb)-positive breast cancer in a host comprising administering an effective amount to a host in need thereof, of a compound selected from: or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 , wherein the host is a human. 3. The method of claim 1 , wherein the compound is administered in combination with another chemotherapeutic agent. 4. The method of claim 3 , wherein the chemotherapeutic agent does not rely on cellular proliferation for its anti-cancer activity. 5. The method of claim 2 , wherein the compound is or a pharmaceutically acceptable salt thereof. 6. The method of claim 5 , wherein the compound is administered in combination with another chemotherapeutic agent. 7. The method of claim 2 , wherein the compound is or a pharmaceutically acceptable salt thereof. 8. The method of claim 7 , wherein the compound is administered in combination with another chemotherapeutic agent. 9. The method of claim 2 , wherein the compound is or a pharmaceutically acceptable salt thereof. 10. The method of claim 9 , wherein the compound is administered in combination with another chemotherapeutic agent.
Assignees
Inventors
Classifications
Spiro-condensed systems · CPC title
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
ortho- or peri-condensed with heterocyclic rings · CPC title
Spiro-condensed systems · CPC title
Ortho-condensed systems · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10376519B2 cover?
- This invention is in the area of tricyclic lactam compounds for and methods of treating selected Rb-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities. In one aspect, treatment of select R…
- Who is the assignee on this patent?
- G1 Therapeutics Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5377. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Aug 13 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).